Does UnitedHealthcare Cover Dayvigo (Lemborexant)?

UnitedHealthcare Formulary Placement for Dayvigo

On most UnitedHealthcare commercial PPO and HMO formularies, Dayvigo sits at Tier 3 (preferred brand). This means the drug is covered but carries a higher copay than Tier 1 generics or Tier 2 preferred generics. UHC publishes its formulary lookup tool annually, and plan-specific tier placement can shift at each renewal cycle.

Tier 3 copays on UHC commercial plans typically fall between $30 and $75 per fill, though coinsurance-based designs may charge 25% to 40% of the negotiated price instead. Employer-sponsored plans sometimes negotiate a lower tier or waive prior authorization entirely, so checking your specific Summary of Benefits is the first step. The FDA-approved prescribing information for Dayvigo lists two strengths (5 mg and 10 mg), both usually grouped under the same formulary tier.

Dayvigo belongs to the dual orexin receptor antagonist (DORA) class. The only other DORA currently marketed in the United States is suvorexant (Belsomra), which often occupies the same or an adjacent tier on UHC plans. A 2020 indirect comparison published in the Journal of Clinical Sleep Medicine found that lemborexant 10 mg showed numerically greater improvements in sleep-onset latency than suvorexant 20 mg, a point that can support a formulary exception request if Belsomra is preferred on your particular plan.

Prior Authorization Requirements

UnitedHealthcare requires prior authorization for Dayvigo on the majority of its commercial plans. The PA process is rated moderate in difficulty, meaning approval is common when documentation is complete but delays occur with missing clinical information.

Your prescriber will need to submit evidence of an insomnia diagnosis meeting DSM-5 criteria for chronic insomnia disorder, which requires symptoms at least three nights per week for three or more months. UHC PA criteria also typically require documentation that non-pharmacologic approaches, specifically cognitive behavioral therapy for insomnia (CBT-I), have been considered. The American Academy of Sleep Medicine (AASM) clinical practice guideline recommends CBT-I as first-line treatment, and insurers increasingly reference this guideline in coverage policies.

Standard documentation a prescriber should include with the PA request:

1. Duration and severity of insomnia symptoms
2. Prior trials of generic sleep agents with dates, doses, and reasons for discontinuation
3. Notation of any CBT-I referral or completion
4. Comorbidities that may influence drug selection (e.g., history of complex sleep behaviors with Z-drugs)

PA turnaround at UHC is generally 48 to 72 hours for standard requests. Urgent requests, where the prescriber attests that delay could cause serious harm, must receive a decision within 24 hours under most state regulations. The Centers for Medicare & Medicaid Services has also pushed for faster electronic PA processing, and UHC has adopted real-time electronic prior authorization for some drug classes through its Optum Rx platform.

Step Therapy: What You Must Try First

Most UnitedHealthcare plans enforce step therapy before approving Dayvigo. Typically, you must have tried and failed (or have a documented contraindication to) at least one first-line generic insomnia medication. The agents that satisfy this step vary by plan but usually include one of the following:

Generic zolpidem (Ambien) is the most commonly required first step. Eszopiclone (Lunesta, now available as generic) and generic trazodone also satisfy the requirement on many UHC formularies. Plans rarely require failure of more than one agent, though some employer-customized designs mandate trials of two generics.

The clinical rationale for step therapy has limits. The SUNRISE-1 trial (N=1,006) compared lemborexant 5 mg and 10 mg against placebo and zolpidem ER 6.25 mg in adults aged 55 and older. At one month, lemborexant 10 mg reduced wake-after-sleep-onset (WASO) by 20.1 minutes more than placebo, while zolpidem ER reduced WASO by only 11.6 minutes more than placebo. This head-to-head data gives prescribers a strong argument when a patient responds poorly to zolpidem.

If your prescriber documents specific safety concerns with Z-drugs, such as a history of parasomnias, falls in elderly patients, or substance use disorder, step therapy can often be overridden. The FDA's 2023 boxed warning update for Z-drugs regarding complex sleep behaviors (sleepwalking, sleep-driving) strengthens override requests for patients with relevant risk factors.

How to Appeal a UnitedHealthcare Denial for Dayvigo

A denied PA does not mean the end of the road. UnitedHealthcare's appeal process follows a structured two-level internal pathway followed by an external independent review.

Level 1 internal appeal. You or your prescriber must file within 180 days of the denial. Include a letter of medical necessity explaining why Dayvigo is specifically appropriate. Cite clinical trial evidence: the SUNRISE-2 trial (N=949) demonstrated that lemborexant maintained statistically significant improvements in sleep onset and sleep maintenance over 12 months, with a safety profile distinct from benzodiazepine receptor agonists. UHC must respond to Level 1 appeals within 30 calendar days for standard requests or 72 hours for expedited appeals.

Level 2 internal appeal. If Level 1 is denied, you can escalate within 60 days. New clinical information strengthens this filing. If the patient has tried and documented failure of suvorexant as well as a Z-drug, include those records. A 2022 systematic review in Sleep Medicine Reviews concluded that DORAs as a class show favorable benefit-risk profiles compared with benzodiazepine receptor agonists for long-term use, particularly in older adults.

External review. After exhausting internal appeals, federal law under the Affordable Care Act grants you the right to request review by an independent review organization (IRO). The IRO decision is binding on UHC. External reviews are resolved within 45 days for standard cases or 72 hours for expedited cases.

A peer-to-peer review, where your prescriber speaks directly with a UHC medical director, can be requested at any stage. Many denials are reversed at this step alone when the prescriber presents the clinical rationale clearly. Document every interaction with dates and reference numbers.

Cost Without Insurance and Savings Options

Dayvigo's manufacturer list price runs approximately $320 per month for a 30-day supply of either the 5 mg or 10 mg strength. Cash-pay pricing through discount programs averages around $85 per month, a significant reduction.

Eisai offers the Dayvigo Savings Card for commercially insured patients. Eligible patients may pay as little as $0 per prescription, with the savings card covering the difference between the copay and a set threshold (typically up to $150 per fill). This card cannot be used with government insurance programs including Medicare Part D, Medicaid, or Tricare, per federal anti-kickback statute regulations.

For uninsured patients, Eisai's patient assistance program may provide Dayvigo at no cost to qualifying individuals below certain income thresholds. Application details are available through the Dayvigo product website or by calling the manufacturer directly. Independent foundations such as the Patient Access Network Foundation occasionally offer copay assistance for sleep disorder medications, though fund availability fluctuates.

Pharmacy choice also matters. Mail-order through Optum Rx (UHC's affiliated PBM) often provides a 90-day supply at a lower per-unit cost than retail fills. Some UHC plans waive one copay tier for mail-order prescriptions, effectively moving Dayvigo from a Tier 3 to a Tier 2 cost for the member.

Clinical Evidence Supporting Formulary Exception Requests

When standard coverage channels fail, a formulary exception request asks UHC to cover Dayvigo at a lower tier or without step therapy. Strong clinical evidence makes these requests more likely to succeed.

The SUNRISE-1 trial remains the cornerstone study. In 1,006 adults aged 55 and older, lemborexant 5 mg and 10 mg both significantly improved sleep-onset latency (SOL) and WASO compared to placebo. The 10 mg dose also outperformed zolpidem ER 6.25 mg on WASO. These results are particularly relevant for older adults, in whom Z-drug risks are elevated. The American Geriatrics Society Beers Criteria lists benzodiazepines and Z-drugs as potentially inappropriate for adults 65 and older due to fall risk and cognitive impairment.

The SUNRISE-2 long-term extension showed that lemborexant's efficacy persisted through 12 months without evidence of tolerance. Discontinuation did not produce rebound insomnia, a finding that differentiates DORAs from benzodiazepine receptor agonists. The FDA label for Dayvigo specifically notes the absence of next-morning residual effects at the 5 mg dose based on driving-simulation studies, a safety advantage for patients who must drive or operate machinery early in the day.

A pooled analysis published in Sleep confirmed that lemborexant improved patient-reported outcomes including sleep quality, total sleep time, and daytime functioning across both key trials. Including patient-reported outcome data in your exception request addresses the "medical necessity" standard that UHC reviewers apply.

UnitedHealthcare Medicare Advantage and Dayvigo

Coverage under UHC Medicare Advantage (MA) plans differs from commercial plans. MA formularies are governed by CMS regulations and follow a separate review process. On most UHC MA Part D formularies, Dayvigo appears on Tier 3 or Tier 4, with prior authorization required.

The coverage gap ("donut hole") can significantly increase out-of-pocket costs for MA members. Under the Inflation Reduction Act provisions that took effect in 2025, the annual Part D out-of-pocket cap is $2,000, which limits total yearly exposure. Patients who reach catastrophic coverage pay $0 for covered drugs for the remainder of the calendar year.

Medicare members cannot use manufacturer copay cards. Instead, they should explore the Medicare Extra Help (Low-Income Subsidy) program if household income is below 150% of the federal poverty level. State pharmaceutical assistance programs (SPAPs) offer additional support in some states and can be layered on top of Part D coverage.

For MA-specific appeals, the timeline is tighter. Standard appeals must be resolved within 7 calendar days, and expedited appeals within 72 hours, per CMS regulations at 42 CFR § 423.590. An independent review entity (IRE) handles external appeals for Part D drugs.

Safety Considerations That Affect Coverage Decisions

UHC medical reviewers weigh safety data when evaluating PA requests. Prescribers who address common safety questions proactively in the PA documentation improve approval odds.

Dayvigo's most common adverse effects in trials were somnolence (reported in 10% of patients on 10 mg vs. 1% on placebo), headache, and abnormal dreams, based on SUNRISE-1 and SUNRISE-2 pooled safety data. The incidence of complex sleep behaviors was low (<1%) across clinical development, and the FDA label carries a standard class warning for DORAs rather than the boxed warning applied to Z-drugs.

Drug interactions require attention. Lemborexant is metabolized primarily by CYP3A. The prescribing information contraindicates concomitant use with strong CYP3A inhibitors (e.g., itraconazole, clarithromycin) and recommends dose adjustment with moderate CYP3A inhibitors. UHC PA reviewers may flag these interactions during utilization review. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics quantified the interaction magnitude, showing that fluconazole (a moderate CYP3A inhibitor) increased lemborexant AUC approximately 4-fold, supporting the label's recommendation to limit the dose to 5 mg when co-administered.

Abuse potential is a consideration. Lemborexant is classified as Schedule IV under the Controlled Substances Act, the same schedule as zolpidem and suvorexant. Human abuse-potential studies included in the FDA review showed that lemborexant 30 mg (three times the maximum approved dose) produced drug-liking scores similar to zolpidem 30 mg. At approved doses, abuse signals in post-marketing surveillance have been minimal according to the FDA Adverse Event Reporting System.